pubs.acs.org/joc
CHART 1. Selected RALs
Access to Resorcylic Acid Lactones via Phosphonate
Based Intramolecular Olefination
Carmela Napolitano, Patrick McArdle, and
Paul V. Murphy*
School of Chemistry, National University of Ireland,
Galway, University Road, Galway, Ireland
Received June 1, 2010
and L-783,2778).9 It can thus be argued that the RAL frame-
work is privileged10 and that analogues of these natural prod-
ucts should be of interest for screening in bioassays. Besides
their important biological properties, the RALs are of interest
from the synthetic point of view.11
Zearalenone, isolated in 1962 from the fungus Gibberella
zeae,12 was the first member of the RAL family to attract the
attention of both chemists and biologists due to its potent
agonism of the estrogen receptor. Zearalenone was shown to
adopt a conformation that mimics the steroid and competes
with estradiol binding to the estrogen receptor. As a result
of its interesting biological properties, several groups have
developed syntheses of this natural product,13 and it has served
as a testing ground for macrocyclization methodologies such as
the Corey-Nicolaou macrolactonization,14 Masamune’s thio-
ester-lactonization,15 ring-closing metathesis (RCM),16 and
more recently late stage aromatization-macrocyclization.17
An approach to resorcylic acid lactones is described, ex-
ploiting an intramolecular olefination reaction for the gen-
eration of the 14-membered macrolactone. The synthetic
route gave zearalenone precursors, and the preparations of
other RAL analogues, trans- and cis-resorcylides are in-
cluded, the latter being prepared by photoisomerization of
the trans-isomer. β-Haloketone derivatives were also pre-
pared in a highly stereoselective manner by conjugate
addition of chloride or bromide to the E-enone using boron
trichloride and boron tribromide, respectively.
(8) Zhao, A.; Lee, S. H.; Mojena, M.; Jenkins, R. G.; Patrick, D. R.;
Huber, H. E.; Goetz, M. A.; Hensens, O. D.; Zink, D. L.; Vilella, D.;
Dombrowski, A. W.; Lingham, R. B.; Huang, L. J. Antibiot. 1999, 52, 1086.
(9) Winssinger, N.; Barluenga, S. Chem. Commun. 2007, 22.
(10) (a) Hirschmann, R. Angew. Chem., Int. Ed. 1991, 30, 1278. (b) Koch,
M. A.; Waldmann, H. Drug Discovery Today 2005, 10, 471.
(11) For selected syntheses of aigialomycin D, see: (a) Yang, Z.-Q.; Geng, X;
Solit, D.; Pratilas, C. A.; Rosen, N.; Danishefsky, S. J. J. Am. Chem. Soc. 2004,
126, 7881. (b) Geng, X.; Danishefsky, S. J. Org. Lett. 2004, 6, 413. (c) Lu, J.; Ma,
J.; Xie, X.; Chen, B.; She, X.; Pan, X. Tetrahedron: Asymm. 2006, 17, 1066. (d)
Calo, F.; Richardson, J.; Barrett, A. G. M. Org. Lett. 2009, 11, 4910. For
hypothemycin and LL-Z1640-2, see: (e) Tatsuta, K.; Takano, S.; Sato, T.;
ꢀ
Nakano, S. Chem. Lett. 2001, 172. (f) Selles, P.; Lett, R. Tetrahedron Lett.
2002, 43, 4621. (g) Selles, P.; Lett, R. Tetrahedron Lett. 2002, 43, 4627. (h) Dakas,
P.-Y.; Jogireddy, R.; Valot, G.; Barluenga, S.; Winssinger, N. Chem.;Eur. J.
2009, 15, 11490. For L-783,277, see: (i) Hofmann, T.; Altmann, K.-H. Synlett
2008, 10, 1500. (j) Choi, H. G.; Son, J. B.; Park, D.-S.; Ham, Y. J.; Hah, J.-M.;
Sim, T. Tetrahedron Lett. 2010, 51, 4942–4946.
(12) Stob, M.; Baldwin, R. S.; Tuite, J.; Andrews, F. N.; Gillette, K. G.
Nature 1962, 196, 1318.
(13) For selected syntheses of zearalenone, see: (a) Taub, D; Girotra,
N. N.; Hoffsommer, R. D.; Kuo, C. H.; Slates, H. L.; Weber, S.; Wendler,
N. L. Tetrahedron 1968, 24, 2443. (b) Takahashi, T.; Ikeda, H.; Tsuji, J.
Tetrahedron Lett. 1981, 22, 1363 and references therein. (c) Hitchcock, S. A.;
ꢀ
The resorcylic acid lactones (RALs, Chart 1) are endowed
with a breadth of biological activity. Compounds within this
class span from being transcription factor modulators (zearale-
none1 and zearalenol2) to HSP90 inhibitors (radicicol3 and
pochonin D4) and reversible (aigialomycin D5) as well as
irreversible kinase inhibitors (hypothemycin,6 LL-Z1640-2,7
(1) Miksicek, R. J. J. Steroid Biochem. Mol. Biol. 1994, 49, 153.
(2) Shier, W. T. Rev. Med. Vet. (Toulouse, Fr.) 1998, 149, 599.
(3) (a) Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.;
Toft, D.; Neckers, L. M. Cell Stress Chaperones 1998, 3, 100. (b) Sharma,
S. V.; Agatsuma, T.; Nakano, H. Oncogene 1998, 16, 2639.
(4) Moulin, E.; Zoete, V.; Barluenga, S.; Karplus, M.; Winssinger, N.
J. Am. Chem. Soc. 2005, 127, 6999.
ꢁ
Pattenden, G. Tetrahedron Lett. 1990, 31, 3641. (d) Solladie, G.; Maestro,
M. C.; Rubio, A.; Pedregal, C.; Carreno, M. C.; Garcia Ruano, J. L. J. Org.
~
Chem. 1991, 56, 2317. (e) Kalivretenos, A.; Stille, J. K.; Hegedus, L. S. J. Org.
Chem. 1991, 56, 2883. (f) Wang, Z. Q.; Tian, S. K. Chin. Chem. Lett. 1997, 8,
591. (g) Nicolaou, K. C.; Wissinger, N.; Pastor, J.; Murphy, F. Angew.
Chem., Int. Ed. 1998, 37, 2534 and references therein.
(5) Barluenga, S.; Dakas, P.-Y.; Ferandi, Y.; Meijer, L.; Winssinger, N.
Angew. Chem., Int. Ed. 2006, 118, 4055.
(6) Tanaka, H.; Nishida, K.; Sugita, K.; Yoshioka, T. Jpn. J. Cancer Res.
1999, 90, 1139. (b) Schirmer, A.; Kennedy, J.; Murli, S.; Reid, R.; Santi, D. V.
Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4234.
(7) Ninomiya-Tsuji, J.; Kajino, T.; Ono, K.; Ohtomo, T.; Matsumoto,
M.; Shiina, M.; Mihara, M.; Tsuchiya, M; Matsumoto, K. J. Biol. Chem.
2003, 278, 18485.
(14) Corey, E. J.; Nicolaou, K. C. J. Am. Chem. Soc. 1974, 96, 5614.
(15) Masamune, S.; Kamata, S.; Schilling, W. J. Am. Chem. Soc. 1975, 97,
3515.
€
(16) Furstner, A.; Thiel, O. R.; Kindler, N.; Bartkowska, B. J. Org. Chem.
2000, 65, 7990.
(17) Navarro, I.; Basset, J.-F.; Hebbe, S.; Major, S. M.; Werner, T.;
€
Howsham, C.; Brackow, J.; Barrett, A. G. M. J. Am. Chem. Soc. 2008, 130,
10293.
7404 J. Org. Chem. 2010, 75, 7404–7407
Published on Web 10/12/2010
DOI: 10.1021/jo100998b
r
2010 American Chemical Society